Floatz logo

Flotufolastat F-18

Biochemically Recurrent Prostate Carcinoma

Jonsson Comprehensive Cancer CenterradiopharmaceuticalPhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

114 Active assets in the Biochemically Recurrent Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
LEUPROLIDE
Mayo Clinic
Phase 4BBB
Enzalutamide
Pfizer
Phase 4BBB
Degarelix
Baptist Health South Florida
Phase 3BBB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BBB
Abiraterone Acetate
Mayo Clinic
Phase 4BBB

View all 50 →

Same molecule, other indications

Flotufolastat F-18 is also rated in:

prostate cancerDormant
BB
Indicative ·
71 / 100
View asset →
metastatic prostate carcinomaDormant
B
Indicative ·
63 / 100
View asset →
prostate adenocarcinomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →